Keyword: Memorial Sloan Kettering Cancer Center
Laura Sepp-Lorenzino, Chief Scientific Officer, Intellia Therapeutics
Biosims haven't worked, experts say. Instead, it's time to for an independent body to set fair biologic prices after the drugs lose exclusivity.
A new study suggests that the consistency of payments from drugmakers to doctors matters the most when it comes to swaying prescribing habits.
A new paper in the Journal of the National Cancer Institute highlights a lucrative strategy that may not grab many headlines.
Pharma makes more from platinum pricing in the U.S. than it spends on research around the world, a new study shows.
Big Pharma might not like billionaire John Arnold’s latest move any more than they did his first. After helping cost-effectiveness watchdog ICER get started, Arnold is backing a patient group's effort to publicize people's struggles to afford needed meds.
Here’s a radical solution for hepatitis C treatment in the U.S.: The government could buy Gilead Sciences. Price: $156 billion. Payoff: Curing hep C patients at one-third the cost.